Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.76M Sell
22,052
-1,621
-7% -$578K 0.19% 90
2025
Q4
$7.75M Sell
23,673
-2,052
-8% -$651K 0.18% 91
2025
Q3
$7.26M Sell
25,725
-1,371
-5% -$398K 0.17% 97
2025
Q2
$7.57M Sell
27,096
-2,411
-8% -$683K 0.2% 83
2025
Q1
$9.19M Buy
29,507
+3,795
+15% +$1.12M 0.26% 61
2024
Q4
$6.7M Sell
25,712
-43
-0.2% -$12.8K 0.2% 78
2024
Q3
$8.3M Buy
25,755
+657
+3% +$215K 0.26% 64
2024
Q2
$7.84M Buy
25,098
+594
+2% +$175K 0.27% 62
2024
Q1
$6.97M Buy
24,504
+264
+1% +$77.2K 0.25% 63
2023
Q4
$6.98M Sell
24,240
-1,155
-5% -$315K 0.28% 60
2023
Q3
$6.83M Buy
25,395
+3,616
+17% +$902K 0.33% 53
2023
Q2
$4.84M Sell
21,779
-300
-1% -$69.6K 0.26% 68
2023
Q1
$5.34M Buy
22,079
+6,401
+41% +$1.57M 0.34% 57
2022
Q4
$4.12M Buy
15,678
+6,753
+76% +$1.81M 0.37% 53
2022
Q3
$2.01M Buy
8,925
+195
+2% +$47.3K 0.32% 62
2022
Q2
$2.12M Sell
8,730
-163
-2% -$39.9K 0.34% 66
2022
Q1
$2.15M Buy
8,893
+3,945
+80% +$906K 0.26% 69
2021
Q4
$1.11M Buy
+4,948
New +$1.04M 0.31% 75

Other funds holding AMGN

Metis Global Partners's AMGN Position: Q1 2026 in Review

Metis Global Partners reduced its Amgen (AMGN) stake by 6.8% in Q1 2026, selling an estimated $578K and leaving 22,052 shares worth $7.76M. The position accounts for 0.19% of the portfolio, ranked #90.

Metis Global Partners first reported a position in AMGN in Q4 2021 and has held it in 18 quarters since. The position peaked at $9.19M in Q1 2025. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Metis Global Partners held 22,052 shares of Amgen worth $7.76M as of Q1 2026.
  • Metis Global Partners sold 1,621 Amgen shares in Q1 2026, an estimated $578K.
  • Amgen made up 0.19% of Metis Global Partners's portfolio in Q1 2026, its #90 holding.
  • Metis Global Partners first reported a position in Amgen in Q4 2021 and has held it in 18 quarters since.
  • Metis Global Partners's Amgen position peaked at $9.19M in Q1 2025.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Metis Global Partners's 13F filing for Q1 2026, filed 7 May 2026.